Search Instructions:
* Filter the ENTIRE resource library: Choose a OR a to sort all resources.
* Choose Search Items : to filter one collection or perform complex queries.
* Choose Browse by Topic to search by one or more Topics.
Browse Items (73 total)
-
Creator: Stone, John H., Matthew J. Frigault, Naomi J. Serling-Boyd, Ana D. Fernandes, Liam Harvey, Andrea S. Foulkes, Nora K. Horick, Brian C. Healy, Ruta Shah, Ana Maria Bensaci, Ann E. Woolley, Sarah Nikiforow, Nina Lin, Manish Sagar, Harry Schrager, David…
Subject: Research
Item Type: Publication
Date Last Updated: 2020-10-21
Description: The efficacy of interleukin-6 receptor blockade in hospitalized patients with coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is unclear. -
Creator: Strampe, Jamie, Danny A. Asogun, Emily Speranza, Meike Pahlmann, Ali Soucy, Sabrina Bockholt, Elisa Pallasch, Beate Becker-Ziaja, Sophie Duraffour, Nahid Bhadelia, Yemisi Ighodalo, Jennifer Oyakhilome, Emmanuel O. Omomoh, Thomas Olokor, Donatus I.…
Subject: Research
Item Type: Publication
Date Last Updated: 2021-01-20
Description: Lassa fever is endemic in several west African countries. Case-fatality rates ranging from 21% to 69% have been reported. The pathophysiology of the disease in humans and determinants of mortality remain poorly understood. We aimed to determine host… -
Creator: the ACTT-1 Study Group Members
Subject: Research
Item Type: Publication
Date Last Updated: 2020-11-05
Description: We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection.A response to this article was published:Dolin, Raphael,… -
Creator: the COVID-19 Genomics UK (COG-UK) consortium
Subject: Personnel Management
Item Type: Publication
Date Last Updated: 2021-08-27
Description: The SARS-CoV-2 delta (B.1.617.2) variant was first detected in England in March, 2021. It has since rapidly become the predominant lineage, owing to high transmissibility. It is suspected that the delta variant is associated with more severe disease…Example only: NETEC provides this item for reference purposes but does not endorse its content. Newer versions may be in place at the providing institution.
-
Creator: the GS-US-540-5773 Investigators
Subject: Research
Item Type: Publication
Date Last Updated: 2020-11-05
Description: We conducted a randomized, open-label, phase 3 trial involving hospitalized patients with confirmed SARS-CoV-2 infection, oxygen saturation of 94% or less while they were breathing ambient air, and radiologic evidence of pneumonia. -
Creator: The Medical Letter on Drugs and Therapeutics
Subject: Treatment & Care
Item Type: Publication
Date Last Updated: 2021-07-15
Description: COVID-19 Vaccine Comparison Chart (online only) effectiveness by vaccine and by variant. -
Creator: the mRNA-1273 Study Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-04-06
Description: Interim results from a phase 3 trial of the Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine indicated 94% efficacy in preventing coronavirus disease 2019 (Covid-19). -
Creator: the Overcoming COVID-19 Investigators
Subject: Treatment & Care
Item Type: Publication
Date Last Updated: 2021-06-16
Description: The assessment of real-world effectiveness of immunomodulatory medications for multisystem inflammatory syndrome in children (MIS-C) may guide therapy. -
Creator: the Oxford COVID-19 Vaccine Trial Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-03-30
Description: A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against this variant. -
Creator: the Oxford University Hospitals Staff Testing Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-02-11
Description: The relationship between the presence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the risk of subsequent reinfection remains unclear.Example only: NETEC provides this item for reference purposes but does not endorse its content. Newer versions may be in place at the providing institution.